AKT1 and diffuse large B-cell lymphoma: investigated the role of SIRT6 in diffuse large B-cell lymphoma (DLBCL) and confirmed that SIRT6 enhances tumorigenesis and drug resistance by activating the PI3K/Akt pathway (213).